Polarean Imaging gets first order for 'Xenoview'

26th Apr 2023 12:46

(Sharecast News) - Medical imaging technology company Polarean Imaging announced on Wednesday that it has received its first order for a gas-blend cylinder for the production of 'Xenoview', or xenon Xe 129 hyperpolarised, from Cincinnati Children's Hospital Medical Center.

The AIM-traded firm said Xenoview is the only hyperpolarised contrast agent approved by the US Food and Drug Administration (FDA) for use with magnetic resonance imaging (MRI), for the evaluation of lung ventilation in both adults and paediatric patients aged 12 years and older.

It said the cylinder was expected to provide adequate doses for over 100 patient scans.

Cincinnati Children's, which conducted much of the pioneering research in adolescent children, planned to begin scanning hospital clinic patients in May.

"Since receiving FDA approval at the end of 2022, we have been working diligently to clear the path for commercial distribution of our proprietary gas blend to sites that already have Xenon MRI infrastructure," said chief executive officer Richard Hullihen.

"We are delighted to secure our first sale of a cylinder and cartons of dose delivery bags for clinical use as we continue to execute our commercial plan."

At 1307 BST, shares in Polarean Imaging were down 1.43% at 24.15p.

Reporting by Josh White for Sharecast.com.